论文部分内容阅读
目的探讨血管活性物质尾加压素Ⅱ(UⅡ)在冠心病患者体内的作用。方法 40例冠心病患者作为冠心病组(稳定型心绞痛10例,不稳定型心绞痛21例,急性心肌梗死9例),20例健康体检者作为健康对照组,采用放射免疫法测定两组的血浆UⅡ水平。结果健康对照组的静脉血浆UⅡ的含量为(3.71±1.32)pg/ml,冠心病组患者的血浆UⅡ含量为(1.37±1.03)pg/ml,两组比较差异有统计学意义(P<0.05)。冠心病组内稳定型心绞痛、不稳定型心绞痛及急性心肌梗死患者的静脉血UⅡ水平分别为(2.62±1.21)、(1.38±0.82)、(1.05±0.48)pg/ml,三组比较差异有统计学意义(P<0.05)。结论 UⅡ可能参与冠心病发病,其在冠心病的发生、发展、预后的研究还只处于初步探讨阶段,有待临床进一步研究。
Objective To investigate the role of vasopressin Ⅱ (UⅡ) in patients with coronary heart disease. Methods Forty patients with coronary heart disease were enrolled in this study. Coronary heart disease (10 cases of stable angina pectoris, 21 cases of unstable angina pectoris, 9 cases of acute myocardial infarction) and 20 healthy controls were selected as healthy control group. Radioimmunoassay U Ⅱ level. Results The content of UⅡ in venous plasma was (3.71 ± 1.32) pg / ml in healthy control group and (1.37 ± 1.03) pg / ml in coronary heart disease group, the difference was statistically significant (P <0.05 ). The levels of UⅡin venous blood in patients with coronary heart disease were (2.62 ± 1.21), (1.38 ± 0.82) and (1.05 ± 0.48) pg / ml, respectively. There were significant differences among the three groups Statistical significance (P <0.05). Conclusions UII may be involved in the pathogenesis of coronary heart disease. The study on the occurrence, development and prognosis of coronary heart disease is only in the initial stage of exploration and awaits further clinical study.